New drug cocktail aims to save lungs in scleroderma patients
NCT ID NCT06297096
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether combining two drugs, nintedanib and tocilizumab, works better than standard treatments (like mycophenolate) for people with systemic sclerosis (scleroderma) who also have lung scarring. The trial will enroll 86 adults and follow them for 56 weeks, measuring lung function and imaging changes. The goal is to slow down lung damage and improve outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nintedanib and tocilizumab combination
What this could lead to
If successful, this combination could offer a more effective treatment option to slow lung damage in people with systemic sclerosis and interstitial lung disease.
What could go wrong
This is a relatively small Phase 3 trial (86 people), and the combination may cause side effects like diarrhea or liver issues. It is not a cure, and long-term benefits are uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centrum Wsparcia Badań Klinicznych
RECRUITINGWarsaw, Masovian Voivodeship, 02-637, Poland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact